将加强海外法律、金融、物流等海外综合服务。 据央视新闻报道，9月12日，国务院常务会议召开，研究完善海外综合服务体系。 威达信集团亚洲区首席商务官柯灵芸（Joan Collar）近期也对第一财经记者表示："中国企业的出海意 愿强烈。在这一过程中，企业不仅着眼于品牌国际化，更致力于提升在国际市场中的份额。它们普遍认 为，出海与国际化是势不可挡的发展趋势。中国在多个领域具备全球竞争力，包括半导体、汽车制造、 新能源以及生物科技和生物燃料等行业，均拥有显著优势，能够为全球市场提供高质量的产品与服 务。" 在此背景下，王雪坤称："当前全球经济艰难复苏，产业竞争不断加剧，贸易投资壁垒也越来越多。这 一大环境下，企业出海面临的不确定、难预料的因素明显增加，所以企业对高质量的海外综合服务的需 求也越来越迫切。" "海外综合服务体系的不断完善将有效引领企业积极稳妥地开展海外市场，推动我国产业链供应链国际 合作走深走实，对深化高水平对外开放、服务构建新发展格局具有重大意义。"他称。 会议指出，要着眼于为出海企业参与国际合作与竞争提供有力支撑，进一步完善海外综合服务体系。统 筹法律、金融、物流等领域服务资源，丰富服务产品，构建服 ...

Group 1: QDII Fund Overview - As of September 12, the total number of QDII funds reached 314, with a total scale of 673 billion yuan, an increase of 141 billion yuan from the beginning of the year, representing a growth rate of 26.5% [1] - Among these, there are 215 equity QDII funds with a scale of 567.7 billion yuan, which accounts for the highest proportion in terms of both number and scale [1] - The significant growth in QDII fund scale this year reflects an increased demand for global asset allocation and improved risk tolerance among investors, influenced by the performance of certain QDII funds [1] Group 2: Performance of QDII Funds - The Hong Kong stock market has performed well this year, contributing to the strong performance of several QDII funds, with 25 funds showing a net value growth rate exceeding 80%, and some surpassing 100% [1] - Thematic funds focusing on innovative drugs and biotechnology have shown particularly strong performance [1] - Market experts attribute the strong performance of QDII funds to ample liquidity in the Hong Kong market and a robust valuation recovery, especially in sectors like innovative drugs, consumption, and technology [1] Group 3: Biopharmaceutical Industry Insights - The biopharmaceutical sector, including gene editing and synthetic biology, is recognized as a key driver for the development of new productive forces in China and is crucial for building a healthy China [2] - The long-term development of the biopharmaceutical industry is fundamentally driven by rigid demand, making it an attractive investment area for many investors [2] - Recent favorable policies in the domestic pharmaceutical industry support the development of innovative drugs across the entire chain, accelerating industry transformation [2]

南非比勒陀利亚大学研发出新型皮肤替代产品 中新网约翰内斯堡9月12日电 南非广播公司12日报道称，南非比勒陀利亚大学新研发出一种新型皮肤替 代产品"无细胞真皮支架(ADS)"，为未来3D生物打印天然皮肤铺平道路，成为传统皮肤移植的替代方 案。 该研究负责人哈菲扎·帕卡尔(Doctor Hafiza Parkar)介绍，无细胞真皮支架是一种用于严重创口的皮肤替 代产品，能够模拟人体皮肤，在动物实验中已显示出加速愈合的效果。 帕卡尔说，它的作用是为机体提供一个框架，以便长出新的健康组织。动物实验显示，它能减少移植中 常见的排斥反应，同时加快愈合速度，对于烧伤、溃疡等复杂创面尤其有效。(完) 来源：中国新闻网 编辑：陈俊明 广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview")，看更多精彩财经资讯。 ...

Core Viewpoint - The article highlights the achievements of 35 innovators under the age of 35 in various fields such as climate and energy, artificial intelligence, biotechnology, computing, and materials science, showcasing their groundbreaking contributions and potential impact on their respective industries [6][11][60]. Climate and Energy - Innovators in this sector are developing advanced technologies for decarbonization, with applications across shipping, fashion, and other industries. They are also exploring new methods for sustainable energy and innovative uses for carbon capture [11]. - Iwnetim Abate is working on producing ammonia using underground heat and pressure, aiming to reduce carbon emissions associated with traditional ammonia production, which contributes 1% to 2% of global CO2 emissions [13]. - Sarah Lamaison's company, Dioxycle, is developing a method to produce chemicals using electricity instead of fossil fuels, significantly reducing greenhouse gas emissions [16][17]. - Gaël Gobaille-Shaw's Mission Zero focuses on direct air capture technology to extract CO2 from the atmosphere, while his second company, Supercritical, aims to produce hydrogen efficiently [19][20]. Artificial Intelligence - Aditya Grover has developed ClimaX, an AI model that predicts weather and climate events, utilizing extensive datasets for improved accuracy [22][23]. - Neel Nanda is researching the interpretability of AI models to ensure their safe and beneficial development, focusing on understanding the decision-making processes of these models [34][35]. - Mark Chen has led advancements in AI models for image processing and code generation, contributing to the development of OpenAI's DALL·E and Codex [38][39]. - Akari Asai is working on retrieval-augmented generation technology to reduce AI hallucinations by allowing models to reference stored data before generating responses [51][52]. Biotechnology - Christian Kramme's company, Gameto, is developing artificial ovarian technology to assist IVF patients, aiming to reduce hormonal injections and stress during the process [62][63]. - Kevin Eisenfrats founded Contraline to create a long-lasting male contraceptive gel, with ongoing clinical trials to validate its effectiveness [64][65]. Computing and Materials Science - Pierre Forin's company, Calcarea, is developing a system to capture and store CO2 emissions from ships, with plans for commercial deployment by 2027 or 2028 [28][29]. - Neeka Mashouf's Rubi Laboratories is innovating a method to produce textiles by extracting CO2 directly from the atmosphere, aiming for sustainable fashion solutions [25][26].

近日，北京赛维森国际生物科技有限公司（"赛维森生物科技"）推出品牌"悦秘境"，凭借医研多企协同 创新模式，依托多项专利技术，以更安全、高效的解决方案，重新定义了女性私密护理的新标准，展现 了硬核科技带来的产品革新。 值得一提的是，赛维森生物科技持续强化供应链布局和品质管控，悦秘境抑菌液的关键原材料全部来自 拥有专利技术的生物科技公司，比如广州富煜陇生物科技有限公司（下称"富煜陇生物科技"）和广州昆 仑生物科技发展有限公司（"昆仑生物科技"）。 随着"她经济"蓬勃发展，当代中国女性越来越注意健康护理，加上90后、00后成为消费主力的双重驱动 下，女性消费市场正驶入增长快车道。 传统私护产品长期面临着吸收效率与安全残留的双重困境。市场调研显示，私处护理液在女性私护品市 场中占比高达48.8%，但多数产品采用的凝胶或乳霜剂型存在两大问题：一是有效成分难以均匀覆盖黏 膜组织，影响吸收效率；二是未吸收成分易在体内形成残留，引发刺激或感染风险。 作为赛维森生物科技联合三甲医院临床专家共同研发的创新产品，悦秘境抑菌液的诞生正是瞄准了这些 行业痛点，其核心突破在于采用了"温敏相变技术"这一医药级创新成果。这项技术借鉴了组织工 ...

领航医药生物科技(0399.HK)今日早盘一度大跌22.12%至0.405港元，股价创7月21日以来近2个月新低。 领航医药生物科技昨日晚间公告，内容有关公司与中国北方证券集团有限公司(作为配售代理)所订立日期为2025年8月21日的配售协议，以按配售价每股配 售股份0.415港元认购最多1.45亿股公司配售股份。董事会宣布，由于配售协议所载的先决条件未能于2025年9月11日或之前达成，配售协议已失效且配售事 项将不会进行。 据悉，领航医药生物科技今年8月21日曾公告，拟发行1.45亿股配售股份净筹5882.5万港元。公司拟将配售事项所得款项净额全数用作集团的于发展区块链技 术业务资金。公告发布翌日(8月22日)，该股大幅收涨10.87%。(格隆汇) ...

美国劳工部 11 日发布数据显示，8 月消费者价格指数（CPI）同比上涨 2.9%，核心 CPI 同比增长 3.1%，大体符合市场预期，这一数据强化了市场对美联储降息的押注。 若降息周期开启，美元走弱或将推动资金回流新兴市场，港股作为外资占比较高的离岸市场，有望迎来 增量资金加持，而科技板块作为流动性敏感型资产，通常率先受益于宽松预期。 科技全产业链——港股通科技ETF基金（159101）； 互联网龙头——恒生互联网ETF（513330）。 每日经济新闻 此外，降息可能刺激全球风险偏好上升，提振科技成长板块的市场情绪。科技型企业弹性和成长属性 强，在宽松环境中往往能展现出更强的上涨潜力。 综合来看，美国通胀数据强化政策转向信号，港股科技板块或迎来估值与资金面的双重驱动。 【港股科技相关ETF】 利率环境转向宽松有助于降低港股科技企业的融资成本，尤其是生物科技、互联网等研发投入较高的行 业，其估值折现率压力减轻，长期盈利预期有望修复。 ...

Market Performance - The Hang Seng Index rose by 1.53% at midday on the 12th [2] - The Hang Seng Tech Index increased by 2.18% [2] - The Hong Kong Stock Connect ETF (159318) gained 0.77% [2] - The Hong Kong Tech ETF (159751) saw an increase of 0.94% [2] Sector Performance - The metals and mining sector, along with the machinery manufacturing sector, showed strong gains [2] - The diversified REITs and biotechnology sectors experienced the largest declines [2] Individual Stock Movements - Baidu Group-SW surged by 8.54% [2] - China Hongqiao increased by 6.06% [2] - Alibaba-WR rose by 6.03% and Alibaba-W by 5.93% [2] - China Aluminum gained 5.92% [2] - Luoyang Molybdenum rose by 5.28% [2] - Kangfang Biotech increased by 4.38% [2] - Yimeng Biotech-B fell by 5.18% [2] - Hongteng Precision Technology dropped by 5.47% [2] - Yaojie Ankang-B surged over 55% [2] - Evergrande Property increased by 30.43% [2]

Core Viewpoint - The study presents a novel method for real-time diagnosis of cholangiocarcinoma (CCA) by combining optical fiber biosensors based on bile clusterin with digestive endoscopy, addressing the urgent need for improved diagnostic techniques for this aggressive cancer type [2][10]. Summary by Sections Diagnosis Challenges - Cholangiocarcinoma is a highly malignant tumor with a poor prognosis, characterized by late diagnosis due to non-specific early symptoms, resulting in a 5-year survival rate of only 7%-20% [2]. Research Findings - The research team identified clusterin (CLU) as a promising biomarker for CCA through proteomic analysis of bile and cell supernatants, highlighting its overexpression in various cancers [5]. - The optical fiber biosensor technology, particularly surface plasmon resonance (SPR), was utilized for its high sensitivity and stability in detecting biological markers [5]. Methodology - The study involved 583 subjects and two rounds of proteomic analysis to screen and validate biomarkers for CCA, leading to the development of an SPR-based optical fiber biosensor [6]. - The biosensor demonstrated a high correlation coefficient of 0.989 and could accurately detect varying concentrations of CLU, with a detection time of 2 seconds and an area under the curve (AUC) of 0.854 [7]. Clinical Application - The CLU optical fiber biosensor was successfully integrated with digestive endoscopy, allowing for real-time in vivo diagnosis of CCA, with results aligning with postoperative pathology findings in patients [8][10].

Core Insights - Absci (ABSI.US) announced a collaboration with Oracle (ORCL.US) and AMD (AMD.US) to accelerate AI-driven drug development [1] - The partnership will utilize Oracle's AI infrastructure and AMD's hardware in Absci's generative AI Drug Creation Platform [1] - The CEO of Absci emphasized that this collaboration will enhance the efficiency of delivering new therapies to patients and establish a technological foundation for next-generation AI-driven drug development processes [1] Company Developments - Absci is based in Vancouver, Washington, and focuses on biotechnology [1] - The announcement coincided with the Oracle Health and Life Sciences Summit held from September 9 to 11 in Orlando, Florida [1] - At the summit, Oracle showcased advancements in healthcare technology, including AI capabilities in its Oracle Fusion Cloud Application, aimed at streamlining supply chain operations in the healthcare industry [1]